Blood test for EBV in NK/T-cell lymphoma
Part of Blood & lymphatic, Cancer, Infections clinical trials.
This study looks at whether a simple blood test can find signs of the Epstein-Barr virus (EBV) that may help doctors better understand your lymphoma. It aims to see if this blood test can be useful in monitoring the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been recently diagnosed with extranodal NK/T cell lymphoma.
- The diagnosis must be confirmed by a tissue sample (biopsy).
- You must sign a consent form and be willing to follow the study schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells (T cells) that are modified to find and attack cells infected with the Epstein-Barr virus (EBV). It is for people with certain blood cancers or chronic active EBV infection that has not improved with standard treatments.
This study collects medical information and blood samples from people with Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases to better understand how these conditions progress and respond to treatment. It includes a retrospective part (looking back at medical records) and a prospective part (following people forward in time).
This early-phase study tests a lab-made immune cell treatment (cytotoxic T-lymphocytes) for certain lymphomas and related diseases that test positive for the Epstein-Barr virus (EBV). It may help your immune system attack EBV-infected cancer cells, especially after the cancer has come back or when transplant isn’t suitable.
This trial tests a new cell therapy (TCR-T cells) for people with EBV-positive lymphoma that has not responded to standard treatments or has come back. The therapy uses your own immune cells that have been specially trained to find and attack cancer cells carrying the EBV virus.
This study tests an Epstein-Barr virus (EBV) blood antibody and an EBV DNA test to help screen people at higher risk for nasopharyngeal cancer. It may find signs earlier in certain families where cancer runs.
This is an early-stage study testing a new immune-based treatment for people with conditions caused by the Epstein-Barr virus (EBV), such as chronic active EBV or post-transplant lymphoproliferative disease. The study aims to see if the treatment is safe and can help control the disease.
Hear when a new Extranodal Natural Killer T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.